Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.43 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PER2 | O15055 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6334079 | 0.95 | TSHR (0.49) | TSHRKMT2AHTTPIK3CDPLA2G10 | |
| SCHEMBL11042645 | 0.94 | TSHR (0.47) | TSHRKMT2AHTTPIK3CDPLA2G10 | |
| SCHEMBL6361822 | 0.84 | PLA2G10 (0.41) | TSHRKMT2AHTTPLA2G10PLA2G5 | |
| SCHEMBL7555011 | 0.83 | TSHR (0.38) | TSHRKMT2AHTTPLA2G10PLA2G5 | |
| SCHEMBL3392318 | 0.81 | TSHR (0.59) | TSHRKMT2AHTTPIK3CDALDH1A1 | |
| SCHEMBL11259716 | 0.80 | TSHR (0.63) | TSHRKMT2AHTTPIK3CDALDH1A1 | |
| SCHEMBL5592121 | 0.79 | PLA2G10 (0.39) | TSHRKMT2APLA2G10PLA2G5ALDH1A1 | |
| SCHEMBL4206491 | 0.79 | DTYMK (0.49) | TSHRKMT2AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL21389414 | 0.79 | ADRA1D (0.45) | TSHRKMT2AHTTALDH1A1KDM4E | |
| SCHEMBL6282329 | 0.79 | PLA2G10 (0.47) | KMT2APLA2G10PLA2G5ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116621755-A | Synthesis method of piracetam related substances | 山东玉满坤生物科技有限公司 | 2023-08-22 | — | — | CN | disclosed |
| WO-2022159576-A1 | ANTI-EGFR ANTIBODY-DRUG CONJUGATES | ABBVIE INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| WO-2020132597-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-8415373-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2013-04-09 | — | — | US | disclosed |
| EP-2342182-B1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2012-11-14 | — | — | EP | disclosed |
| US-8242134-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-08-14 | — | — | US | disclosed |
| US-8173639-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-05-08 | — | — | US | disclosed |
| EP-2150534-B1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2012-01-11 | — | — | EP | disclosed |
| US-20110288120-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-11-24 | — | — | US | disclosed |
| US-20100076016-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2010-03-25 | — | — | US | disclosed |
| US-7563912-B2 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of Levetiracetam and analogues | UCB PHARMA, S.A. (BE) | 2009-07-21 | — | — | US | disclosed |
| US-20090143402-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| EP-1419144-B1 | OXOPYRROLIDINE COMPOUNDS, PREPARATION OF SAID COMPOUNDS AND THEIR USE IN THE MANUFACTURING OF LEVETIRACETAM AND ANALOGUES | UCB PHARMA SA (BE) | 2008-10-08 | — | — | EP | disclosed |
| US-20070142647-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues | ATES CELAL | 2007-06-21 | — | — | US | disclosed |
| US-20060258734-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of Levetiracetam and analogues | UCB PHARMA, S.A. (BE) | 2006-11-16 | — | — | US | disclosed |
| US-7122682-B2 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues | UCB, S.A. (BE) | 2006-10-17 | — | — | US | disclosed |
| US-20040204476-A1 | Oxopyrrolidine compounds, preparations of said compounds and their use in the manufacturing of levetiracetam and analogues | UCB PHARMA, S.A. (BE) | 2004-10-14 | — | — | US | disclosed |
| EP-1419144-A2 | OXOPYRROLIDINE COMPOUNDS, PREPARATION OF SAID COMPOUNDS AND THEIR USE IN THE MANUFACTURING OF LEVETIRACETAM AND ANALOGUES | UCB, S.A. (BE) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003014080-A2 | OXOPYRROLIDINE COMPOUNDS, PREPARATION OF SAID COMPOUNDS AND THEIR USE IN THE MANUFACTURING OF LEVETIRACETAM AND ANALOGUES | UCB, S.A. (BE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076016-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNQ3, KCNK3, GRIK3 | TSHR 1316/4885KMT2A 891/4885HTT 636/4885 |
| US-20090143402-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNQ3, KCNK3, GRIK3 | TSHR 1227/4885KMT2A 1850/4885HTT 3474/4885 |
| US-20110288120-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNK3, KCNQ3, KCNN3 | TSHR 1855/4885KMT2A 1863/4885HTT 4494/4885 |
| US-20040204476-A1 | Oxopyrrolidine compounds, preparations of said compounds and their use in the manufacturing of levetiracetam and analogues | CYP2C19, CYP2C9, TPMT | TSHR 2070/4885KMT2A 188/4885HTT 1570/4885 |
| US-20060258734-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of Levetiracetam and analogues | TPMT, CYP2C9, OTC | TSHR 1645/4885KMT2A 62/4885HTT 1898/4885 |
| US-20070142647-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues | CYP2D6, OTC, CYP2B6 | TSHR 1681/4885KMT2A 133/4885HTT 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.